← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › ANTIEMETICS AND ANTINAUSEANTS › ANTIEMETICS AND ANTINAUSEANTS › Other antiemetics
nabilone
A04AD11
Adult Dosing
- Chemotherapy-induced nausea and vomiting: 1 or 2 mg twice daily
- Initiate dose the night before or 1-3 hours before the first chemotherapy dose
- Continue during the entire course of chemotherapy and, if needed, for 24 hours after the last dose
- Maximum daily dose: 6 mg given in divided doses
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Management of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments
Mechanism of Action
- Synthetic cannabinoid that acts as a cannabinoid receptor (CB1 and CB2) agonist
- Inhibits vomiting center in the central nervous system through complex mechanisms involving cannabinoid receptors
Contraindications
- Known hypersensitivity to nabilone or any component of the formulation
- History of any psychopathic disorder (due to potential for exacerbating psychiatric symptoms)
- Active substance abuse or dependence
Adverse Reactions
- Drowsiness and dizziness
- Euphoria and mood alterations
- Dry mouth
- Ataxia and coordination impairment
- Orthostatic hypotension
- Concentration difficulties
- Visual disturbances
Drug Interactions
- CNS depressants (alcohol, sedatives, hypnotics, opioids, anxiolytics): Increased risk of profound sedation, respiratory depression, and cognitive impairment
- Sympathomimetics, cocaine, and anticholinergics: May result in additive tachycardia, hypertension, or drowsiness
- Metabolized primarily by CYP enzymes; potential for pharmacokinetic interactions with potent CYP inhibitors or inducers
Curated Content: Needs Vetting Before Put to Clinical Use